In 45 patients with relapsed/refractory AML treated with CC-90009, a dose-dependent decrease in GSPT1 levels was observed in T cells and peripheral blood cells, with a greater decrease in levels as the dose increased. This evidence concerns the gene GSPT1 and acute myeloid leukemia.